Sunday - March 08, 2015

First ever guidelines on managing PCOS released in India

  • Statistics reveal that in India 1 out of every 5 women in the reproductive age and as high as 2 out of every 5 adolescents are diagnosed with PCOS
  • A PCOS prevalence in India is as high as 22% which is much higher as compared to that in developed countries
  • The guidelines are a first-of-its-kind, developed on basis of India-specific evidence and expert consensus, specially catering to the needs of Indian women with PCOS
  • Approx. 5000 doctors all over India will pledge to improve the quality of life of their PCOS patients and help them step out with confidence

 

New Delhi, March 08, 2015–On the occasion of Women’s Day, Bayer Zydus Pharma supported the Indian Fertility Society (IFS) todisseminate the first ever guidelines for Management of Polycystic Ovary Syndrome (PCOS) in India at the PCOS India Summit 2015 held in Delhi. This summit was a multi-specialty interactive scientific symposium bringing together leading medical practitioners from the field of gynecology, dermatology, endocrinology, paediatrics and radiology.

 

According to an article published in the Fertility Science and Research Journalof the Indian Fertility Society in 2014, 1 out of every 5 women in the reproductive age and as high as 2 out of every 5 adolescents in India are diagnosed with PCOS. Polycystic Ovary Syndrome (PCOS) is a complex metabolic, endocrine and reproductive disorder that results in overproduction of male hormones, and is associated with insulin resistance (IR). The common symptoms of PCOS range from menstrual disorders, infertility, acneand increased facial hair to metabolic syndrome (MS). The prevalence rate of PCOS in India is as high as 22% which is much higher as compared to that in developed countries where it is approximately 5- 10% .

 

Dr. Sonia Malik, President of Indian Fertility Society and Principal author of the Guidelines of Management of PCOS in India says, “Given higher risk of PCOS in Indian women and the heterogeneous and complex nature of the disease, there was a need for a sustained, multi-pronged, multi-disciplinary approach for the optimal management of PCOS.These guidelines are a culmination of the hard work and diligent efforts on part of a multidisciplinary panel of doctors from various parts of India.”

 

The recently developed guidelines for PCOS management are the first- of- its- kind in India. These guidelines engage medical practitioners from multiple-disciplinesand spell out an algorithmic approach to treating PCOS.

 

As mentioned earlier, PCOS is a metabolic disorder with variedsymptoms, ranging from irregular periods, acne and facial hair, infertility, obesity and is one of the predisposing factors for Diabetes Mellitus. The multitude of symptom complexes result in repeated visits to doctors from various disciplines, including gynaecologists, paediatricians, endocrinologists, skin specialists; thus complicating the situation further. These guidelines aim at simplifying patient management, through involvement of various medical specialties suggesting symptom- and age-based approaches towards optimal treatment of patients.

 

Dr. Malik at the summit encouraged the physicians in India to optimize PCOS management by adhering to these guidelines.

 

Bayer Zydus Pharma intends to further disseminatethese guidelines to approximately 5000 doctors across India.“We at Bayer are committed toimprove the health and well-being of our patients. We intend to take these guidelines further by way of educational programs for doctors across cities in India. This initiative is in line with our mission at Bayer – Science for a Better Life” says Angel- Michael Evangelista, Managing Director – Bayer Zydus Pharma

 

About Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 20,0 billion (2014), is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 60,700 employees (Dec 31, 2014) and is represented in more than 100 countries. More information is available at www.healthcare.bayer.com.

 

About Bayer Zydus Pharma

Bayer Zydus Pharma, the joint venture company of Bayer HealthCare and Zydus Cadila, is backed by strong research and development and a novel therapeutic approach. Focused on patients' healthcare needs in India, Bayer Zydus Pharma offers innovative healthcare solutions in the area of women's healthcare, general medicine, specialty medicine and diagnostic imaging.

 

For further details :

 

Contact :

Mandira Viegas

Corporate Communications

Bayer Group in India

Email : mandira.veigas@bayer.com

Contact no. : 022 2531 1092